Comprehensive microrna expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma

Thyroid

Volumn 23, Issue 11, 2013, Pages 1383-1389

  Dettmer, Matthias ^a   Perren, Aurel ^b   Moch, Holger ^c   Komminoth, Paul ^d   Nikiforov, Yuri E ^a   Nikiforova, Marina N ^a,e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d TRIEMLI HOSPITAL   (Switzerland)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 146 5P; MICRORNA 146B 3P; MICRORNA 181 2 3P; MICRORNA 221; MICRORNA 222; MICRORNA 222 5P; MICRORNA 375; MICRORNA 551B; MICRORNA 99B 3P; MOLECULAR MARKER; RADIOACTIVE IODINE; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RNA ISOLATION; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; UPREGULATION; VALIDATION STUDY;

ADULT; CARCINOMA; CARCINOMA, PAPILLARY, FOLLICULAR; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; THYROID GLAND; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84887462115     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0632     Document Type: Article

References (41)

1. DeLellis R, Lloyd R, Heitz P, Eng C 2004 Pathology and Genetics of Tumours of Endocrine Organs. DeLellis R, Lloyd R, Heitz P, Eng C (eds). IARC Press, Lyon [World Health Organization classification of tumours].
2. Nikiforov YEB, Paul W, Thompson LD, eds. 2009 Diagnostic Pathology and Molecular Genetics of the Thyroid. First edition Lippincott Williams & Wilkins, Philadelphia.
3. Chem KT, Rosai J 1977 Follicular variant of thyroid papillary carcinoma: a clinicopathologic study of six cases. Am J Surg Pathol 1:123-130.
4. Chetty R 2011 Follicular patterned lesions of the thyroid gland: a practical algorithmic approach. J Clin Pathol 64: 737-741.
5. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE 2006 Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30: 216-222. (Pubitemid 43740191)
6. Nikiforov YE 2011 Molecular analysis of thyroid tumors. Mod Pathol 24:S34-43.
7. Pennelli G, Vianello F, Barollo S, Pezzani R, Merante Boschin I, Pelizzo MR, Mantero F, Rugge M, Mian C 2011 BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma. Thyroid 21:1393-1396.
8. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ, Nikiforov YE 2005 Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24:6646-6656. (Pubitemid 41486795)
9. Igci YZ, Arslan A, Akarsu E, Erkilic S, Igci M, Oztuzcu S, Cengiz B, Gogebakan B, Cakmak EA, Demiryurek AT 2011 Differential expression of a set of genes in follicular and classic variants of papillary thyroid carcinoma. Endocr Pathol 22:86-96.
10. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR 2005 Micro-RNA expression profiles classify human cancers. Nature 435:834-838. (Pubitemid 40839735)
11. Bartel DP 2004 MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297.
12. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE 2008 MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 93:1600-1608. (Pubitemid 351656494)
13. Dettmer M, Vogetseder A, Durso MB, Moch H, Komminoth P, Perren A, Nikiforov YE, Nikiforova MN 2013 MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. J Clin Endocrinol Metab 98:E1-E7.
14. Nikiforova MN, Chiosea SI, Nikiforov YE 2009 MicroRNA expression profiles in thyroid tumors. Endocr Pathol 20: 85-91.
15. Nikiforova MN, Caudill CM, Biddinger P, Nikiforov YE 2002 Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol 10:15-22. (Pubitemid 34245954)
16. Livak KJ, Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408. (Pubitemid 34164012)
17. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M, Negrini M, Croce CM, Fusco A 2006 MicroRNA deregulation in human thyroid papillary carcinomas. Endocrine-related cancer 13:497-508. (Pubitemid 43886672)
18. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A 2005 The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102: 19075-19080. (Pubitemid 43049568)
19. Tetzlaff MT, Liu A, Xu X, Master SR, Baldwin DA, Tobias JW, Livolsi VA, Baloch ZW 2007 Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol 18:163-173. (Pubitemid 351384379)
20. Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE, Nikiforova MN 2011 MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol 18:2035-2041.
21. Giricz O, Reynolds PA, Ramnauth A, Liu C, Wang T, Stead L, Childs G, Rohan T, Shapiro N, Fineberg S, Kenny PA, Loudig O 2012 Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. J Pathol 226:108-119.
22. Nishikawa E, Osada H, Okazaki Y, Arima C, Tomida S, Tatematsu Y, Taguchi A, Shimada Y, Yanagisawa K, Yatabe Y, Toyokuni S, Sekido Y, Takahashi T 2011 miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer. Cancer Res 71: 6165-6173.
23. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, Magalhaes J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simoes M 2005 Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446:589-595. (Pubitemid 40922263)
24. Adeniran AJ, Zhu ZW, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE 2006 Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216-222. (Pubitemid 43740191)
25. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, Croce CM 2012 Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci USA 109:3024-3029.
26. Lam EK, Wang X, Shin VY, Zhang S, Morrison H, Sun J, Ng EK, Yu J, Jin H 2011A microRNA contribution to aberrant Ras activation in gastric cancer. Am J Trans Res 3:209-218.
27. Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, Zhang WG, Nan KJ, Song TS, Huang C 2009 MicroRNA profiling of human gastric cancer. Mol Med Report 2:963-970.
28. Favreau AJ, Sathyanarayana P 2012 miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia. Leuk Res 36:334-341.
29. He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, Li PY, Song YH, Lin JS 2012 MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene 31:3357-3369.
30. Lin M, Chen W, Huang J, Gao H, Ye Y, Song Z, Shen X 2011 MicroRNA expression profiles in human colorectal cancers with liver metastases. Oncol Rep 25:739-747.
31. Bray I, Tivnan A, Bryan K, Foley NH, Watters KM, Tracey L, Davidoff AM, Stallings RL 2011 MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett 303: 56-64.
32. Tanic M, Zajac M, Gomez-Lopez G, Benitez J, Martinez-Delgado B 2012 Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NFkappaB pathway. Breast Cancer Res Treat 134:41-51.
33. Feber A, Xi L, Pennathur A, Gooding WE, Bandla S, Wu M, Luketich JD, Godfrey TE, Litle VR 2011 MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg 91:1523-1530.
34. Kalimutho M, Blanco GD, Di Cecilia S, Sileri P, Cretella M, Pallone F, Federici G, Bernardini S 2011 Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. Journal of Gastroenterology 46:1391-1402.
35. Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E, Tao J 2012 Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 31:3002-3008.
36. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP 2008 Involvement of micro-RNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7:2152-2159.
37. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262. (Pubitemid 40896444)
38. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762. (Pubitemid 350294294)
39. Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ, Lee YF, Yang KD, Cheng JT, Huang CC, Liu RT 2010 miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid 20:489-494.
40. Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, Evans C, Jensen RV, Moskaluk CA, Dutta A 2011 miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 71:1313-1324.
41. Maurel M, Jalvy S, Ladeiro Y, Combe C, Vachet L, Sagliocco F, Bioulac-Sage P, Pitard V, Jacquemin-Sablon H, Zucman-Rossi J, Laloo B, Grosset CF 2013A functional screening identifies five micrornas controlling glypican-3: role of mir-1271 down-regulation in hepatocellular carcinoma. Hepatology 57:195-204.